{
    "ticker": "NTRB",
    "name": "NantKwest, Inc.",
    "description": "NantKwest, Inc. is a clinical-stage biotechnology company focused on the development of immune-based therapies to treat cancer and other serious diseases. Founded in 2015, NantKwest is dedicated to harnessing the power of the immune system to create innovative treatments that target and eradicate tumors. The company's lead product candidates are designed to leverage its proprietary Natural Killer (NK) cell technology, which is engineered to enhance the body\u2019s innate immune response. NantKwest is at the forefront of developing off-the-shelf immunotherapies that can be administered to patients without the need for personalized cell processing. This approach not only aims to improve clinical outcomes but also seeks to provide therapies that are more accessible and cost-effective. With a strong pipeline of product candidates in various stages of clinical trials, NantKwest is committed to advancing its research and development efforts. The company collaborates with leading academic institutions and research organizations to explore new avenues for cancer treatment and other diseases. NantKwest's mission is to translate groundbreaking science into transformative therapies that can significantly impact patient lives and contribute to the fight against cancer.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Culver City, California, USA",
    "founded": "2015",
    "website": "https://www.nantkwest.com",
    "ceo": "Dr. Patrick Soon-Shiong",
    "social_media": {
        "twitter": "https://twitter.com/NantKwest",
        "linkedin": "https://www.linkedin.com/company/nantkwest/"
    },
    "investor_relations": "https://ir.nantkwest.com",
    "key_executives": [
        {
            "name": "Dr. Patrick Soon-Shiong",
            "position": "CEO"
        },
        {
            "name": "Dr. Richard M. A. Heller",
            "position": "Chief Scientific Officer"
        }
    ],
    "product_categories": [
        {
            "category": "Immunotherapies",
            "products": [
                "NantKwest NK Cell Therapy"
            ]
        }
    ],
    "seo": {
        "meta_title": "NantKwest, Inc. | Immune-Based Cancer Therapies",
        "meta_description": "Explore NantKwest, Inc., a leader in immune-based therapies for cancer treatment. Discover our innovative NK cell technology and pipeline of clinical candidates.",
        "keywords": [
            "NantKwest",
            "Immunotherapy",
            "Cancer Treatment",
            "Natural Killer Cells",
            "Biotechnology",
            "Clinical Trials"
        ]
    },
    "faq": [
        {
            "question": "What does NantKwest specialize in?",
            "answer": "NantKwest specializes in developing immune-based therapies to treat cancer and other serious diseases."
        },
        {
            "question": "Who is the CEO of NantKwest?",
            "answer": "Dr. Patrick Soon-Shiong is the CEO of NantKwest, Inc."
        },
        {
            "question": "Where is NantKwest headquartered?",
            "answer": "NantKwest is headquartered in Culver City, California, USA."
        },
        {
            "question": "What is the main technology used by NantKwest?",
            "answer": "NantKwest utilizes proprietary Natural Killer (NK) cell technology to enhance immune responses against tumors."
        },
        {
            "question": "When was NantKwest founded?",
            "answer": "NantKwest was founded in 2015."
        }
    ],
    "competitors": [
        "CRIS",
        "CLVS",
        "BMY",
        "JNJ"
    ],
    "related_stocks": [
        "AMGN",
        "REGN",
        "GILD",
        "VRTX"
    ]
}